TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
In The News
2023 - 01 - 09
Medicines derived from biological compounds are the fastest-growing class of drugs. We discuss how to accelerate the production of these biologics to a rapid pace. Tune in & enter the world of Bioprocessing 4.0 with Merrilee Whitney, Chris Hwang and Kelvin Lee.
Click here and get inspired: https://www.merckgroup.com/en/future-talk/1734997
In Conversation | Xueming Qian – CEO & Co-Founder, Transcenta
Putting Biologics on the Fast Lane
Industrialization of Highly Intensified Connected/Continuous Biomanufacturing Platform (HiCB) to Address Patient and Business Needs
A CTO's Journey Into Continuous Biomanufacturing
TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors
BioPharm International：Moving Closer to End-to-End Continuous Bioprocessing
